First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 33
- Registration Number
- NCT04564417
- Locations
- 🇫🇷
IGR, Villejuif, Villejuif, France
🇪🇸CUN, Pamplona, Pamplona, Spain
🇫🇷IUCT, Toulouse, Toulouse, France
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 274
- Registration Number
- NCT04317599
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇦🇹Barmherzige Brüder Krankenhaus St. Veit/Glan., St. Veit/Glan, Austria
🇦🇹Medizinische Universität Wien, Vienna, Austria
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 152
- Registration Number
- NCT03887130
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 95
- Registration Number
- NCT03693170
- Locations
- 🇫🇷
AP-HM CHU Timone, Marseille, France
🇫🇷ICO- Site René Gauducheau, Saint-Herblain, France
🇫🇷Hôpital Europeen Georges Pompidou, Paris, France
A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 316
- Registration Number
- NCT03316638
- Locations
- 🇫🇷
IUCT, Toulouse, France
🇫🇷IGR, Villejuif, France
🇪🇸VHIO, Barcelona, Spain
EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Pierre Fabre Medicament
- Registration Number
- NCT02907320
Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 29
- Registration Number
- NCT02518568
Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar Extraction
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 414
- Registration Number
- NCT02382809
Assessment of V0018 1.5 mg Effect on Craving
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 30
- Registration Number
- NCT02359201
Assessment of V0018 2.5 mg Effect on Craving
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 45
- Registration Number
- NCT02357888
© Copyright 2024. All Rights Reserved by MedPath